A Phase 1 study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refractory CLL or Richter's transformation of CLL
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
TG Therapeutics, Inc
Start Date
February 3, 2020
End Date
March 9, 2021
Administered By
Duke Cancer Institute
Awarded By
TG Therapeutics, Inc
Start Date
February 3, 2020
End Date
March 9, 2021